Latest Patent Strategy News

Avecho Biotechnology has exceeded its Phase III CBD insomnia trial recruitment target by 16%, setting the stage for a more robust interim analysis scheduled for June 2026. The company’s commercial partnership with Sandoz AG and strengthened patent portfolio underpin its Australian market strategy.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Codeifai Limited has terminated its exclusive licence with MIT and launched a strategic review of its material science division, signaling a decisive pivot towards digital and AI-driven brand solutions.

Anatara Lifesciences has been granted a key Australian patent for its GaRP gastrointestinal health product, reinforcing its intellectual property portfolio ahead of pivotal clinical trial results expected in March 2025.